Redhill Biopharma has signed a manufacturing deal with two companies in Europe and Canada to ramp up production of its coronavirus treatment candidate, the Israeli drugmaker said on Tuesday.
The company said it was expanding manufacturing capabilities for Opaganib, its experimental cancer drug for which it intends to apply for emergency use in COVID-19 patients, to meet likely demand after it is approved for such use.
Follow Israel Hayom on Facebook and Twitter
Redhill did not disclose terms of the deal or the name of the manufacturing companies.
Opaganib is being currently tested in patients hospitalized with severe COVID-19 pneumonia in two mid-stage trials − one in the United States and another global study that has received approval in six countries including Italy, Russia, UK and Mexico.
Redhill said it was in discussions with the US government agencies for potential funding to support wider production of Opaganib.
Subscribe to Israel Hayom's daily newsletter and never miss our top stories!
